1 |
Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381:333-42.
DOI
|
2 |
Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746-59.
DOI
|
3 |
Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 1988;148:220-7.
DOI
|
4 |
Noonan JA, Kappelgaard AM. The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 2015;83:157-66.
DOI
|
5 |
Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy Family: consequences of germline activation of the RAS/MAPK Pathway. Endocr Rev 2018;39:676-700.
DOI
|
6 |
Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-9.
DOI
|
7 |
El Bouchikhi I, Belhassan K, Moufid FZ, Iraqui Houssaini M, Bouguenouch L, Samri I, et al. Noonan syndrome-causing genes: molecular update and an assessment of the mutation rate. Int J Pediatr Adolesc Med 2016;3:133-42.
DOI
|
8 |
Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5377-81.
DOI
|
9 |
Choi JH, Lee BH, Jung CW, Kim YM, Jin HY, Kim JM, et al. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation. Horm Res Paediatr 2012;77:388-93.
DOI
|
10 |
Tamburrino F, Gibertoni D, Rossi C, Scarano E, Perri A, Montanari F, et al. Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: Patterns of growth, puberty and final height data. Am J Med Genet A 2015; 167A:2786-94.
|
11 |
Binder G. Noonan syndrome, the Ras-MAPK signalling pathway and short stature. Horm Res 2009;71 Suppl 2:64-70.
|
12 |
Jo KJ, Kim YM, Yoon JY, Lee YJ, Han YM, Yoo HW, et al. Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome. Korean J Pediatr 2019;62:274-80.
DOI
|
13 |
Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 2008;159:203-8.
DOI
|